TNFRSF1B and acute myeloid leukemia: In another clinical trial, the same group reported that combined therapy with azacytidine and lenalidomide, the immunomodulatory drug, also contributed to a reduced number of TNFR2+ Tregs and TNFR2 expression on T cells, resulting in the durable clinical remission in AML patients [100].